GT Biotech Fund, LP is a hedge fund based in Memphis, Tennessee. According to its most recent Form D, filed Jul 29, 2026, the fund has sold $233,540,857 of interests to 314 investors since its first sale in Apr 2020. The minimum investment it accepts from an outside investor is $5,000. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Justin Rikard; Darren Kearns; Mary Cornpropst.
Performance
No verified returns have been reported for this fund. Hedge fund returns are not part of SEC filings; managers report them to HedgeMountain directly.
Is this your fund? Report your monthly returns · How performance works
- Total raised
- $233,540,857Cumulative sales reported on Form D
- Investors
- 314
- First sale
- Apr 1, 2020
- Minimum investment
- $5,000
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Justin Rikard; Darren Kearns; Mary Cornpropst
- Latest Form D
- Jul 29, 2026
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and HedgeMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures
Size compared with every hedge fund
Raised more than 78% of the 55 hedge funds based in Tennessee, and more than 71% of all 10,157 that report sales.